A recent study indicated that fadraciclib targeted CDK9 in NB cells, suppressed MYCN transcription, and induced growth arrest, resulting in increased sensitivity to apoptosis when combined with CDK2 inhibition [45]. The gene discussed is MYCN; the disease is neuroblastoma.